A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria.
Antimalarial treatment policy
Artemisinin resistance
Artemisinin-based combination therapy
Framework
Stakeholder engagement
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
17 Jun 2023
17 Jun 2023
Historique:
received:
16
12
2022
accepted:
14
06
2023
medline:
19
6
2023
pubmed:
18
6
2023
entrez:
17
6
2023
Statut:
epublish
Résumé
Recent reports of artemisinin partial resistance from Rwanda and Uganda are worrisome and suggest a future policy change to adopt new anti-malarials. This is a case study on the evolution, adoption, and implementation of new anti-malarial treatment policies in Nigeria. The main objective is to provide perspectives to enhance the future uptake of new anti-malarials, with an emphasis on stakeholder engagement strategies. This case study is based on an analysis of policy documents and stakeholders' perspectives drawn from an empirical study conducted in Nigeria, 2019-2020. A mixed methods approach was adopted, including historical accounts, review of programme and policy documents, and 33 qualitative in-depth interviews and 6 focus group discussions. Based on policy documents reviewed, the adoption of artemisinin-based combination therapy (ACT) in Nigeria was swift due to political will, funding and support from global developmental partners. However, the implementation of ACT was met with resistance from suppliers, distributors, prescribers, and end-users, attributed to market dynamics, costs and inadequate stakeholder engagement. Deployment of ACT in Nigeria witnessed increased developmental partner support, robust data generation, ACT case-management strengthening and evidence on anti-malarial use in severe malaria and antenatal care management. A framework for effective stakeholder engagement for the future adoption of new anti-malarial treatment strategies was proposed. The framework covers the pathway from generating evidence on drug efficacy, safety and uptake; to making treatment accessible and affordable to end-users. It addresses which stakeholders to engage with and the content of engagement strategies with key stakeholders at different levels of the transition process. Early and staged engagement of stakeholders from global bodies to community level end-users is critical to the successful adoption and uptake of new anti-malarial treatment policies. A framework for these engagements was proposed as a contribution to enhancing the uptake of future anti-malarial strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Recent reports of artemisinin partial resistance from Rwanda and Uganda are worrisome and suggest a future policy change to adopt new anti-malarials. This is a case study on the evolution, adoption, and implementation of new anti-malarial treatment policies in Nigeria. The main objective is to provide perspectives to enhance the future uptake of new anti-malarials, with an emphasis on stakeholder engagement strategies.
METHODS
METHODS
This case study is based on an analysis of policy documents and stakeholders' perspectives drawn from an empirical study conducted in Nigeria, 2019-2020. A mixed methods approach was adopted, including historical accounts, review of programme and policy documents, and 33 qualitative in-depth interviews and 6 focus group discussions.
RESULTS
RESULTS
Based on policy documents reviewed, the adoption of artemisinin-based combination therapy (ACT) in Nigeria was swift due to political will, funding and support from global developmental partners. However, the implementation of ACT was met with resistance from suppliers, distributors, prescribers, and end-users, attributed to market dynamics, costs and inadequate stakeholder engagement. Deployment of ACT in Nigeria witnessed increased developmental partner support, robust data generation, ACT case-management strengthening and evidence on anti-malarial use in severe malaria and antenatal care management. A framework for effective stakeholder engagement for the future adoption of new anti-malarial treatment strategies was proposed. The framework covers the pathway from generating evidence on drug efficacy, safety and uptake; to making treatment accessible and affordable to end-users. It addresses which stakeholders to engage with and the content of engagement strategies with key stakeholders at different levels of the transition process.
CONCLUSION
CONCLUSIONS
Early and staged engagement of stakeholders from global bodies to community level end-users is critical to the successful adoption and uptake of new anti-malarial treatment policies. A framework for these engagements was proposed as a contribution to enhancing the uptake of future anti-malarial strategies.
Identifiants
pubmed: 37330469
doi: 10.1186/s12936-023-04622-2
pii: 10.1186/s12936-023-04622-2
pmc: PMC10276382
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
185Subventions
Organisme : Wellcome Trust
ID : 220211
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Ann Med Surg (Lond). 2022 Jul;79:104031
pubmed: 35761818
Glob Heart. 2019 Jun;14(2):173-179
pubmed: 31324372
Malar Res Treat. 2013;2013:176096
pubmed: 24490102
Malar Res Treat. 2011;2011:683167
pubmed: 22312571
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33753339
Trends Parasitol. 2021 Jan;37(1):15-24
pubmed: 33060063
Health Policy Plan. 2004 Nov;19(6):356-70
pubmed: 15459161
N Engl J Med. 2021 Sep 23;385(13):1231-1232
pubmed: 34551233
Lancet Infect Dis. 2022 Jun;22(6):751-753
pubmed: 35276063
Malar J. 2017 May 2;16(1):180
pubmed: 28464945
Bull World Health Organ. 2011 Apr 1;89(4):312-6
pubmed: 21479096
Wellcome Open Res. 2021 Apr 7;6:75
pubmed: 34458588
BMJ. 2012 Feb 27;344:e1316
pubmed: 22371864
Malar J. 2012 Nov 08;11:370
pubmed: 23137141
Environ Innov Soc Transit. 2021 Sep;40:40-59
pubmed: 35106274
Malar J. 2021 Feb 27;20(1):119
pubmed: 33639946
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):203-18
pubmed: 18165494
Lancet Infect Dis. 2021 Aug;21(8):1120-1128
pubmed: 33864801
BMC Public Health. 2022 Apr 30;22(1):864
pubmed: 35490212
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):12-7
pubmed: 11425173
J Trop Med. 2015;2015:189232
pubmed: 26161095
Antimicrob Agents Chemother. 2021 Jan 20;65(2):
pubmed: 33168604
Am J Trop Med Hyg. 2007 Jan;76(1):7-11
pubmed: 17255221
Malar J. 2021 Jul 19;20(1):320
pubmed: 34281562
PLoS One. 2022 Sep 9;17(9):e0273249
pubmed: 36083995
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):193-7
pubmed: 18165492
Health Policy Plan. 2021 Feb 16;35(10):1364-1375
pubmed: 33179027
Malar J. 2022 Feb 12;21(1):42
pubmed: 35151332
Am J Trop Med Hyg. 2021 Sep 07;105(4):1067-1075
pubmed: 34491220
Malar J. 2016 Jun 22;15:331
pubmed: 27334876
Malar J. 2019 Mar 22;18(1):93
pubmed: 30902052
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
Infect Dis Poverty. 2017 Feb 7;6(1):36
pubmed: 28173853
PLoS One. 2021 Aug 31;16(8):e0256567
pubmed: 34464398
N Engl J Med. 2021 Sep 23;385(13):1163-1171
pubmed: 34551228
Malar J. 2007 May 29;6:72
pubmed: 17535417
Malar J. 2021 Jan 19;20(1):48
pubmed: 33468147
Malar J. 2022 Jul 23;21(1):225
pubmed: 35870909